Hyperuricemia and Associated Diseases

Rheumatic Disease Clinics of North America

Volumn 32, Issue 2, 2006, Pages 275-293

  Becker, Michael A ^a   Jolly, Meenakshi ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; URICOSURIC AGENT;

ARTERY DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; STROKE;

ANIMALS; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE MODELS, ANIMAL; HUMANS; HYPERURICEMIA; METABOLIC SYNDROME X;

EID: 33646545069     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.02.005     Document Type: Review

References (141)

1. Fessel J.W. Renal outcomes of gout and hyperuricemia. Am J Med 67 (1979) 74-82
2. Liang M.H., and Fries J.F. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med 88 (1978) 666-670
3. Wyngaarden J.B., and Kelley W.N. Gout and hyperuricemia (1976), Grune & Stratton, New York
4. Gibson T., Waterworth R., Hatfield P., et al. Hyperuricemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol 23 (1984) 276-282
5. Darmavan J., Valkenburg H.A., Muirden K.D., et al. The epidemiology of gout and hyperuricemia in a rural population of Java. J Rheumatol 19 (1992) 1595-1599
6. Ko Y.C., Wang T.N., Tsai L.Y., et al. High prevalence of hyperuricemia in adolescent Taiwan aborigenes. J Rheumatol 29 (2002) 837-842
7. Klemp P., Stansfield S.A., Castle B., et al. Gout is on the increase in New Zealand. Ann Rheum Dis 56 (1997) 22-26
8. Jossa F., Farinaro E., Panico S., et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 8 (1994) 677-681
9. Masuo K., Kawaguchi H., Mikami H., et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42 (2003) 474-480
10. Taniguchi Y., Hayashi T., Tsumura K., et al. Serum uric acid and the risk of hypertension and type 2 diabetes in Japanese men. The Osaka health study. J Hypertens 19 (2001) 1209-1215
11. Nakanishi N., Okamato M., Yoshida H., et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 18 (2003) 523-530
12. Hunt S.C., Stephenson S.H., Hopkins P.N., et al. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 17 (1991) 969-976
13. Grahame R., and Scott J.T. Clinical survey of 354 patients with gout. Ann Rheum Dis 29 (1970) 461-468
14. Rapado A. Relationship between gout and arterial hypertension. Adv Exp Med Biol 41B (1974) 451-459
15. Kahn H.A., Medalie J.H., Neufeld H.N., et al. The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J 84 (1972) 171-182
16. Prebis J.W., Gruskin A.B., Polinsky M.S., et al. Uric acid in childhood essential hypertension. J Pediatr 98 (1981) 702-707
17. Messerli F.H., Frohlich E.D., Dreslinski G.R., et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 93 (1980) 817-821
18. Puig J.G., Miranda M.E., Mateos F.A., et al. Hereditary nephropathy associated with hyperuricemia and gout. Arch Intern Med 153 (1993) 357-365
19. Kanellis J., Watanabe S., Li J.H., et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen activated protein kinase and cyclooxygenase-2. Hypertension 41 (2003) 1287-1293
20. Kanellis J., and Kang D.H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 25 (2005) 39-42
21. Mazzali M., Hughes J., Kim Y.G., et al. Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension 38 (2001) 1101-1106
22. Mazzali M., Kanellis J., Han L., et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure independent mechanism. Am J Physiol Renal Physiol 282 (2002) F991-F997
23. Watanabe S., Kang D.H., Feng L., et al. Uric acid, hominoid evolution and the pathogenesis of salt- sensitivity. Hypertension 40 (2002) 355-360
24. Feig D.I., and Johnson R.J. Hyperuricemia in childhood essential hypertension. Hypertension 42 (2003) 247-252
25. Feig D.I., Nakagawa T., Karumanchi S.A., et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 66 (2004) 1-8
26. Johnson R.J., and Tuttle K.R. Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. Hypertension 35 (2000) E10
27. Johnson R.J., Kang D.H., Feig D., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 41 (2003) 1183-1190
28. Johnson R.J., Rodriguez-Iturbe B., Kang D.H., et al. A unifying pathway for essential hypertension. AJH 18 (2005) 431-440
29. Feig D.I. Uric acid and hypertension in adoloscents. Semin Nephrol 25 (2005) 32-38
30. Kang D.H., and Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 25 (2005) 43-49
31. Sanchez-Lozada L.G., Tapia E., Avila-Casado C., et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283 (2002) F1105-F1110
32. Nakagawa T., Mazzali M., Kang D.H., et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23 (2003) 2-7
33. Kang D.H., Nakawaga T., Feng L., et al. A role of uric acid in the progression of renal disease. J Am Soc Nephrol 13 (2002) 2888-2897
34. Kang D.H., and Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 25 (2005) 43-49
35. Sanchez-Lozada L., Tapia E., Rodriguez-Iturbe B., et al. Hemodynamics of hyperuricemia. Semin Nephrol 25 (2005) 19-24
36. Mazzali M., Kim Y.-G., Suga S., et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 71 (2001) 900-905
37. Reif M.C., Constantiner A., and Levitt M.F. Chronic gouty nephropathy: a vanishing syndrome. N Engl J Med 304 (1981) 535-536
38. Fairbanks L.D., Cameron J.S., Venkat-Raman G., et al. Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease. Q J Med 95 (2002) 597-607
39. McBride M.B., Simmonds H.A., Ogg C.S., et al. Efficacy of allopurinol in ameliorating the progressive renal disease in familial juvenile hyperuricaemic nephropathy (FJHN). A six-year update. Adv Exp Med Biol 431 (1998) 7-11
40. Cameron J.S., and Simmonds H.A. Hereditary hyperuricemia and renal disease. Semin Nephrol 25 (2005) 9-18
41. Dahan K., Vuyst D., Smaers M., et al. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with anornal expression of uromodulin. J Am Soc Nephrol 14 (2003) 2883-2893
42. Segura J., Campo C., and Ruilope L.M. How relevant and frequent is the presence of mild renal insufficiency in essential hypertension?. J Clin Hypertens 4 (2002) 332-336
43. Leoncini G., Viazzi F., Parodi D., et al. Mild renal dysfunction and subclinical cardiovascular damage in primary hypertension. Hypertension 42 (2003) 14-18
44. Staessen J., and for members of the European working party on high blood pressure in the elderly. The determinants and prognostic significance of serum uric acid in elderly patients of the European working party on high blood pressure in the elderly trial. Am J Med 90 (1991) 50s-54s
45. Tomita M., Mizuno S., Yamanaka H., et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 10 (2000) 403-409
46. Iseki K., Oshiro S., Tozawa M., et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hyprtens Res 24 (2001) 691-697
47. Perlstein T.S., Gumieniak O., Hopkins P.N., et al. Uric acid and the state of the intrarenal renin angiotensin system in humans. Kidney Int 66 (2004) 1465-1470
48. Iseki K., Ikemiya Y., Inoue T., et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44 (2004) 642-650
49. Johnson R.J., Kivlighn S.D., Kim Y.G., et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular, and renal disease. Am J Kidney Dis 33 (1999) 225-234
50. Alderman M.H., Cohen H., Madhavan S., et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34 (1999) 144-150
51. Brand F.N., McGee D.L., Kannel W.B., et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 121 (1985) 11-18
52. Abbott R.D., Brand F.N., Kannel W.B., et al. Gout and coronary heart disease: the Framingham study. J Clin Epidemiol 41 (1988) 237-242
53. Culleton B.F., Larson M., Kannel W.B., et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med 131 (1999) 7-13
54. Wannamethee S.G., Shaper A.G., and Whincup P.H. Serum urate and the risk of major coronary heart disaese events. Heart 78 (1997) 147-153
55. Nagahama K., Iseki K., Inoue T., et al. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 27 (2004) 227-233
56. Fang J., and Alderman M.H. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow up study, 1971-1992. JAMA 283 (2000) 2404-2410
57. Bickel C., Rupprecht H.J., Blankenberg S., et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89 (2002) 12-17
58. Yusuf S., and Bosch J. Urate levels as predictor of cardiac deaths: causal relation or mere association?. Eur Heart J 23 (2002) 760-761
59. Wong K.Y., MacWalter R.S., Fraser H.W., et al. Urate predicts subsequent cardiac death in stroke survivors. Eur Heart J 23 (2002) 788-793
60. Tuttle K.R., Short R.A., and Johnson R.J. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 87 (2001) 1411-1414
61. Rich M.W. Uric acid: is it a risk factor for cardiovascular disease?. Am J Cardiol (2000) 1018-1021
62. Madsen T.E., Muhlestein J.B., Carlquist J.F., et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 25 (2005) 45-49
63. Moriarity J.T., Folsom A.R., Iribarren C., et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk In Communities (ARIC) Study. Ann Epidemiol 10 (2000) 136-143
64. Freedman D.S., Williamson D.F., Gunter E.W., et al. Relation of serum uric acid to mortality and Ischemic heart disease. The NHANES 1 Epidemiologic Follow-up study. Am J Epidemiol 141 (1995) 637-644
65. Liese A.D., Hense H.W., Lowel H., et al. Association of serum uric acid with all- cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg Cohort. Epidemiology 10 (1999) 391-397
66. Franse L.V., Pahor M., Bari M.D., et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 18 (2000) 1149-1154
67. Verdecchia P., Schillaci G., Reboldi G., et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36 (2000) 1072-1078
68. Niskanen L.K., Laaksonen D.E., Nyyssonen K., et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle aged men. Arch Intern Med 164 (2004) 1546-1551
69. Hoieggen A., Alderman M.H., Kjeldsen S.E., et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65 (2004) 1041-1049
70. Dahlof B., Devereux R., de Faire U., et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 10 (1997) 705-713
71. Athyros V.G., Elisaf M., Papageorgiou A.A., et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary artery disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Am J Kidney Dis 43 (2004) 589-599
72. Malinow M.R., Levenson J., Giral P., et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyteine concentration. Atherosclerosis 114 (1995) 175-183
73. Hong Y.S., Lee M.J., Kim K.H., et al. The C677 mutation in methylene tetrahydrofolate reductase gene: Correlation with uric acid and cardiovascular risk factors in elderly korean men. J Korean Med Sci 19 (2004) 209-213
74. Mercuro G., Vitale C., Cerquetani E., et al. Effect of hyperuricemia upon endothelial function in patients with increased cardio vascular risk. Am J Cardiol 94 (2004) 932-935
75. Gavin A.R., and Struthers A.D. Hyperuricemia and adverse outcomes in cardiovascular disease. Am J Cardiovasc Drugs 3 (2005) 309-314
76. Yu Z.F., Bruce-Keller A.J., Goodman Y., et al. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 53 (1998) 613-625
77. Chamorro A., Obach V., Cervera A., et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 33 (2002) 1048-1052
78. Lehto S., Niskanen L., Ronnemaa T., et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin dependent diabetes mellitus. Stroke 29 (1998) 635-639
79. Mazza A., Pessina A.C., Pavei A., et al. Predictors of stroke mortality in elderly people from the general population. Eur J Epidemiol 17 (2001) 1097-1104
80. Wang J.G., Staessen J.A., Fagard R.H., et al. Prognostic significance of serum creatinine and uric acid in older chinese patients with isolated systolic hypertension. Hypertension 37 (2001) 1069-1074
81. Weir C.J., Muir S.W., Walters M.R., et al. Serum urate as an independent predictor of poor outome and future vascular events after acute stroke. Stroke 34 (2003) 1951-1956
82. Abuja P.M. Ascorbate prevents pro oxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 446 (1999) 305-308
83. Cherubini A., Polidori M.C., Bregnocchi M., et al. Antioxidant profile and early outcome in stroke patients. Stroke 31 (2000) 2295-2300
84. Tseng C.H. Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes. Diabet Med 21 (2004) 724-729
85. Nieto F.J., Iribarren C., Gross M.D., et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 148 (2000) 131-139
86. Doehner W., Schoene N., Rauchhaus M., et al. Effects of xanthine oxidase inhibition with allopurinol on endothelialfunction and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo controlled studies. Circulation 105 (2002) 2619-2624
87. Anker S.D., Doehner W., Rauchhaus M., et al. Uric acid and survival in chronic heart failure. Circulation 107 (2003) 1991-1997
88. Cicoira M., Zanolla L., Rossi A., et al. Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 143 (2002) 1107-1111
89. Hare J.M., and Johnson R.J. Uric acid predicts clinical outcomes in heart failure. Insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 107 (2003) 1951-1953
90. Cappola T.P., Kass D.A., Nelson G.S., et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104 (2001) 2407-2411
91. Ekelund U.E., Harrison R.W., Shokek O., et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing induced heart failure. Circ Res 85 (1999) 437-445
92. Ukai T., Cheng C.P., Tachibana H., et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing induced heart failure. Circulation 103 (2001) 750-755
93. Struthers A.D., Donnan P.T., Lindsay P., et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospcetive cohort study. Heart 87 (2002) 229-234
94. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 58 (1998) 509-510
95. Facchini F., Chen Y.-D., Hollenbeck C.B., et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266 (1991) 3008-3011
96. Vuorin-Markkola H., and Yki-Jarvonen H. Hyperuricemia and insulin-resistance. J Clin Endocrinol Metab 78 (1994) 25-29
97. Reaven G.M. Role of insulin-resistance in human disease. Diabetes 37 (1988) 1596-1607
98. Denzer C., Muche R., Mayer H., et al. Serum uric acid levels in obese children and adolscents:linkage to testosterone levels and pre metabolic syndome. J Pediatr Endocrinol 16 (2003) 1225-1232
99. Gokcel A., Gumurdulu Y., Karakose H., et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 4 (2002) 49-55
100. Brauer G.W., and Prior I.A.M. A prospective study of gout in New Zealand Maoris. Ann Rheum Dis 37 (1978) 466-472
101. Fessel W.J., and Bar G.D. Uric acid, lean body weight and creatine interactions: results from regression analysis of 78 variables. Semin Arthritis Rheum 7 (1977) 115-121
102. Glynn R.J., Campion E.W., and Silbert J.E. Trends in serum uric acid levels 1961-1980. Arthritis Rheum 26 (1983) 87-93
103. Scott J.T. Obesity and hyperuricaemia. Clin Rheum Dis 3 (1977) 25-35
104. Sturge R.A., Scott J.T., Kennedy A.C., et al. Serum uric acid in England and Scotland. Ann Rheum Dis 36 (1977) 420-427
105. Seidell J.C., Bakx K.C., Deurenberg P., et al. Overweight and chronic illness: a retrospective cohort study with a follow-up of 6-17 years, in men and women of initially 20-50 years of age. J Chronic Dis 39 (1986) 585-593
106. Must A., Jacques P.F., Dallal G.E., et al. Long term morbidity and mortality of overweight adolescents. A follow up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 327 (1992) 1379-1380
107. Loenen H.M., Eshuis H., Lowik M.R., et al. Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch Nutrition Surveillance System). J Clin Epidemiol 43 (1990) 1297-1303
108. Bray G.A. Complications of obesity. Ann Intern Med 103 (1985) 1052-1062
109. Emmerson B.T. Alteration of urate metabolism by weight reduction. Aust N Z J Med 3 (1973) 410-412
110. Gibson T., Waterworth R., Hatfield P., et al. Hyperuricaemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol 23 (1984) 276-282
111. Kannel W.B., and Gordon T. Physiological and medical concomittants of obesity: the Framingham study. In: Bray G.A. (Ed). Obesity in America (1979), DHEW (PHS) Publication 79-359, Bethesda (MD) 125-163
112. Roubenoff R., Klag M.J., Mead L.A., et al. Incidence and risk factors for gout in white men. JAMA 266 (1991) 3004-3007
113. Ogura T., Matsuura K., Matsumoto Y., et al. Recent trends of hyperuricemia and obseity in Japanese male adolescents, 1991 through 2002. Metabolism 53 (2004) 448-453
114. Masuo K., Kawaguchi H., Mikami H., et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42 (2003) 474-480
115. Reynolds P.P., Knapp M.J., Baraf H.S.B., et al. Moonshine and lead. Relationship to the pathogenesis and hyperuricemia in gout. Arthritis Rheum 26 (1983) 1057-1064
116. Dessein P.H., Shipton E.A., Stanwix A.E., et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59 (2000) 539-543
117. Tsunoda S., Kamide K., Minami J., et al. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: Effect of a low energy diet and an insulin sensitizing agent. Am J Hypertens 15 (2002) 697-701
118. Tambascia M.A., Geloneze B., Repetto E.M., et al. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double blind, randomised controlled trial. Diabetes Obes Metab 5 (2003) 338-344
119. Krejs G.J. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord 26 (2002) S34-S37
120. Sjostrom L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004) 2683-2693
121. Donahue R.P., Prineas R., Donahue D.C., et al. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami community health study. Diabetes Care 22 (1999) 1092-1096
122. Ruige J.B., Dekker J., Blum W.F., et al. Leptin and variables of body adiposity, energy balance, and Insulin resistance in a population based study: the Hoorn study. Diabetes Care 22 (1999) 1097-1104
123. Ogura T., Matsura K., Otsuka F., et al. Serum leptin correlates with serum uric acid but not with serum testosterone in non obese male adolescents. Res Commun Mol Pathol Pharm 107 (2000) 55-63
124. Garcia-Lorda P., Bullo M., Vila R., et al. Leptin concentrations do not correlate with fat mass nor with metabolic risk factors in morbidly obese females. Diab Nutr Metab 14 (2001) 329-336
125. Matsubara M., Chiba H., Maruoka S., et al. Elevated serum leptin concentrations in women with hyperurecemia. J Atheroscler Thromb 9 (2002) 28-34
126. Bedir A., Topbas M., Tanyeri F., et al. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J 44 (2002) 527-536
127. Moreno L.A., Pineda I., Rodriguez G., et al. Leptin and metabolic syndrome in obese and non obese children. Horm Metab Res 34 (2002) 394-399
128. Barlow K.A. Hyperlipidemia in primary gout. Metabolism 17 (1968) 289-299
129. Gibson J.T., and Grahame R. Gout, hypertriglyceridemia, and alcohol consumption. Ann Rheum Dis 33 (1974) 109-110
130. Naito H.K., and Mackenzie A.H. Secondary hypertriglyceridemia and hyperlipoproteinemia in patients with primary asymptomatic gout. Clin Chem 25 (1979) 371-375
131. Jiao S., Kameda K., Matsuzawa Y., et al. Hyperlipoproteinemia in primary gout: hyperlipoproteinemic phenotype and influence of alcohol intake and obesity in Japan. Ann Rheum Dis 45 (1986) 308-313
132. Daskalopoulou S.S., Mikhailidis D.P., and Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 55 (2004) 589-612
133. Takahashi S., Yamamoto T., Moriwaki Y., et al. Impaired lipoprotein metabolism in patients with primary gout: influence of alcohol intake and body weight. Br J Rheumatol 33 (1994) 731-734
134. Takahashi S., Yamamoto T., Moriwaki Y., et al. Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Ann Rheum Dis 54 (1995) 90-93
135. Cardona F., Tinahones F.J., Collantes E., et al. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatol 42 (2003) 468-472
136. Clausen J.O., Borch-Johnsen K., Ibsen H., et al. Analysis of the relationship between fasting seum uric acid and the insulin sensitivity index in a population based sample of 380 young healthy caucasians. Eur J Endocrinol 138 (1998) 63-69
137. Rocic B., Vucic-Lovrencic M., Poje N., et al. Uric acid may inhibit glucose induced insulin secretion via binding to an arginine residue in rat pancreatic beta cells. Bioorg Med Chem Lett 15 (2005) 1181-1184
138. Hara H., Egusa G., and Yamakido M. Incidence of non insulin dependent diabetes mellitus and its risk factors in Japanese Americans living in Hawaii and Los Angeles. Diabet Med 13 (1996) S133-S142
139. Lin K.C., Tsai S.T., Lin H.Y., et al. Different progressions of hyperglycemia and diabetes among hyperuricemic men and women in the Kinmen study. J Rheumatol 31 (2004) 1159-1165
140. Chou P., Lin-Chia L., Wu G.S., et al. Progression of type 2 diabetes among high risk groups in Kin-Chen kinmen. Diabetes Care 21 (1998) 1183-1187
141. Nakanishi N., Okamato M., Yoshida H., et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 18 (2003) 523-530